Issue 13, 2025, Issue in Progress

Symmetrical di-substituted phenylamino-s-triazine derivatives as anticancer agents: in vitro and in silico approach

Abstract

A series of symmetrical tri-substituted s-triazine derivatives were designed and synthesized by two different methods (reflux and microwave-assisted methods). The structures of compounds were determined by infrared (IR), nuclear magnetic resonance (1H NMR and 13C NMR), and mass spectrometry. The yield of the microwave-assisted method (91–98%) was significantly higher (about 10%) than that of the reflux method (80–88%) meanwhile the reaction time was significantly shorter (15–30 min). Compound 3b showed good cytotoxic activity against the MCF7 (human breast cancer) cell line with an IC50 value of 6.19 μM. Compounds 3a and 2e showed strong cytotoxic activity against the C26 (colon carcinoma) cell line with IC50 values of 1.21 and 8.28 μM, respectively. Compound 3e showed good cytotoxic activity against both MCF7 and C26 cell lines with IC50 values of 13.74, and 14.66 μM respectively. In particular, compound 2d exhibited the best potent cytotoxic activity among the synthesized compounds against both MCF7 and C26 cell lines with IC50 values of 6.54 and 0.38 μM, respectively. Moreover, compounds 2e, 3a, and 3e showed higher selectivity on cancer cell lines and lower toxicity on BAEC (bovine aorta endothelial) normal cells compared to compounds 2d, 3a, paclitaxel, and doxorubicin. In silico studies revealed five potent compounds with good physicochemical and ADMET profiles and potent interactions with key anticancer targets (EGFR, DHFR, VEGFR2, CDK2, mTOR, and PI3K) compared to reference drugs. This work paved the way for the synthesis of more potent compounds based on the phenylamino-s-triazine scaffold and the exploration of their diverse and potential biological activities as well as their mechanisms of action.

Graphical abstract: Symmetrical di-substituted phenylamino-s-triazine derivatives as anticancer agents: in vitro and in silico approach

Supplementary files

Article information

Article type
Paper
Submitted
02 Dec 2024
Accepted
15 Mar 2025
First published
01 Apr 2025
This article is Open Access
Creative Commons BY-NC license

RSC Adv., 2025,15, 9968-9984

Symmetrical di-substituted phenylamino-s-triazine derivatives as anticancer agents: in vitro and in silico approach

E. Canh Pham, B. Thi Le, A. M. Ngo, L. B. Vong and T. N. Truong, RSC Adv., 2025, 15, 9968 DOI: 10.1039/D4RA08508F

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements